CSIMarket
 
Rani Therapeutics Holdings Inc   (NASDAQ: RANI)
 
Price: $0.8645 $0.01 1.230%
Day's High: $0.9018999934196472 Week Perf: 2.79 %
Day's Low: $ 0.84 30 Day Perf: 7.93 %
Volume (M): 1,155,514 52 Wk High: $ 3.87
Volume (M$): $ 0 52 Wk Avg: $1.09
Open: $0.85 52 Wk Low: $0.44



 Market Capitalization (Millions $) 156
 Shares Outstanding (Millions) 180
 Employees 71
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -6
 Capital Exp. (TTM) (Millions $) 0

Business Description


Rani Therapeutics Holdings Inc is a clinical-stage bio-pharmaceutical company founded in 2012 and headquartered in San Jose, California. The company's core mission is to develop innovative, non-injectable therapies that can be administered orally.

Rani Therapeutics' flagship product is the RaniPill capsule, which is a self-administered drug delivery device designed to replace injections. The RaniPill is packed with tiny needles that are typically made of sugar and dissolve when the capsule is swallowed. When the capsule reaches the stomach, it is designed to inject the medication directly into the intestinal wall where it is absorbed into the bloodstream.

The company is focused on developing oral formulations of large-molecule biologics, such as complex proteins and peptides, which traditionally have to be administered by injection. With its innovative technology, Rani Therapeutics is hoping to change the way medication is delivered, making it easier for patients to receive lifesaving treatment without having to endure painful and inconvenient injections.

In addition to the RaniPill, the company is also developing a range of other novel drug delivery systems, including the RaniNose nasal spray and the RaniPatch transdermal patch.

Rani Therapeutics has received significant financial backing from numerous venture capitalists, including 5AM Ventures, Novartis, and GV (formerly known as Google Ventures). The company has raised more than $142 million to date.

Rani Therapeutics' experienced management team includes highly qualified industry professionals who have a track record of developing and commercializing innovative pharmaceutical products. The company employs over 80 people across its research and development, manufacturing, and business development teams.

Overall, Rani Therapeutics Holdings Inc is a dynamic and growing company that is at the forefront of developing innovative, non-injectable therapies that have the potential to transform the treatment of a range of medical conditions.


   Company Address: 2051 Ringwood Avenue San Jose 95131 CA
   Company Phone Number: 457-3700   Stock Exchange / Ticker: NASDAQ RANI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
INSM   -1.92%    
LLY   -5.97%    
MNKD   -4.33%    
PBYI        0.32% 
TEVA   -5.01%    
VTRS   -0.54%    
• View Complete Report
   



Partnership

Rani Therapeutics Secures Up to $1.085 Billion Collaboration with Chugai Pharmaceutical for Innovative Therapeutics a...

Published Mon, Oct 20 2025 11:10 AM UTC

SAN JOSE, Calif., Oct. 17, 2025 Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a pioneering clinical-stage biotherapeutics company dedicated to the oral delivery of biologics and pharmaceuticals, has officially announced a strategic partnership with Chugai Pharmaceutical Co., Ltd. The collaboration, which is valued at up to $1.085 billion, encompasses the development and...

Announcement

Rani Therapeutics to Highlight Innovations in Oral Biologics at the 2024 Maxim Healthcare Virtual Summit

Published Tue, Oct 8 2024 8:05 PM UTC

In the ever-evolving landscape of biotherapeutics, Rani Therapeutics Holdings, Inc. stands out as a pioneer dedicated to advancing the oral delivery of biologics and pharmaceuticals. As a clinical-stage company, Rani is committed to revolutionizing the way patients access life-saving medications. This commitment will be in the spotlight during the 2024 Maxim Healthcare Virtu...

Shares

Rani Therapeutics Secures $10 Million in Funding to Advance Oral Drug Delivery Technology

Published Mon, Jul 22 2024 12:30 PM UTC

Rani Therapeutics Raises $10 Million in Registered Direct Offering
SAN JOSE, Calif., July 22, 2024 - Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) announced today the pricing of a $10.0 million registered direct offering with a single institutional investor. The offering includes 2,800,000 shares of Rani Therapeutics Class A common stock, pre-funded warrants to purchas...

Partnership

Rani Therapeutics and ProGen Collaborate to Uphold Obesity Treatment with Groundbreaking RaniPill Technology...

Published Mon, Jun 24 2024 11:00 AM UTC

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity TreatmentIn an exciting development for the pharmaceutical industry, Rani Therapeutics has announced a partnership with ProGen to collaborate on the development of a groundbreaking oral obesity treatment. The innovative RT-114 obesity program aims to combine ProGen s FC Fusion protein conjugat...

Clinical Study

Rani Therapeutics Bolsters Oral Delivery of Biologics with RaniPill Capsule

Published Thu, May 9 2024 12:00 PM UTC

Rani Therapeutics Holdings, Inc. (Rani Therapeutics) has recently announced its plan to present groundbreaking clinical and preclinical data on the RaniPill capsule at Digestive Disease Week (DDW) 2024. As a clinical-stage biotherapeutics company, Rani Therapeutics focuses on developing innovative solutions for the oral delivery of biologics and drugs. This article will outl...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 49.10
Price to Sales (Expected) -
Price to Book 4.38
PEG (TTM) -

Financial Strength Current
Quick Ratio 3.5
Working Capital Ratio 3.8
Leverage Ratio (MRQ) 0.66
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -156.15 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) -
Cash 0.24 $
Book Value 0.2 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 44,634
Net Income per Employee (TTM) -510,239
Receivable Turnover Ratio (TTM) 3.1
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.08

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -488.23 %
Net Margin (MRQ) -469.26 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.